Citius Pharma Files 8-K, Confirms Nasdaq Listing for CTXR
Ticker: CTXR · Form: 8-K · Filed: Jan 2, 2024 · CIK: 1506251
| Field | Detail |
|---|---|
| Company | Citius Pharmaceuticals, INC. (CTXR) |
| Form Type | 8-K |
| Filed Date | Jan 2, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: compliance, corporate-governance, exchange-listing
TL;DR
**CTXR filed a routine 8-K, confirming its Nasdaq listing; no new financial news.**
AI Summary
Citius Pharmaceuticals, Inc. filed an 8-K on January 2, 2024, to report on its operations and financial condition, specifically noting its common stock, $0.001 par value, is registered on The Nasdaq Capital Market under the trading symbol CTXR. This filing is a routine update, indicating no major new events but confirming the company's continued compliance and listing status. For investors, this matters because it reaffirms the company's presence on a major exchange, which is crucial for liquidity and visibility, though it doesn't provide new financial performance data.
Why It Matters
This filing confirms Citius Pharmaceuticals' continued listing on The Nasdaq Capital Market, which is important for the stock's trading liquidity and investor confidence. It's a standard compliance update rather than a disclosure of new financial results or significant corporate actions.
Risk Assessment
Risk Level: low — This 8-K is a standard compliance filing and does not disclose any new risks or material changes to the company's operations or financial condition.
Analyst Insight
This filing is a routine compliance update and does not provide new information that would warrant immediate investment action. Investors should continue to monitor for future filings that disclose financial results, clinical trial updates, or other material corporate events.
Key Numbers
- $0.001 — par value per share (the stated par value of Citius Pharmaceuticals' common stock)
Key Players & Entities
- Citius Pharmaceuticals, Inc. (company) — the registrant filing the 8-K
- The Nasdaq Capital Market (company) — the exchange where Citius Pharmaceuticals' common stock is registered
- CTXR (company) — the trading symbol for Citius Pharmaceuticals' common stock
- $0.001 (dollar_amount) — par value of Citius Pharmaceuticals' common stock
- January 2, 2024 (date) — date of earliest event reported and filing date
Forward-Looking Statements
- Citius Pharmaceuticals will continue to maintain its listing on The Nasdaq Capital Market. (Citius Pharmaceuticals, Inc.) — high confidence, target: 2025-01-02
FAQ
What is the purpose of this 8-K filing by Citius Pharmaceuticals, Inc.?
This 8-K filing by Citius Pharmaceuticals, Inc. is a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, reporting on 'Results of Operations and Financial Condition' and 'Other Events' as of January 2, 2024. It primarily serves as a routine compliance update, confirming the company's registration details and listing on The Nasdaq Capital Market.
What is the trading symbol and exchange for Citius Pharmaceuticals, Inc.'s common stock?
Citius Pharmaceuticals, Inc.'s common stock trades under the symbol CTXR and is registered on The Nasdaq Capital Market, as stated in the filing under 'Securities registered pursuant to Section 12(b) of the Act'.
What is the par value of Citius Pharmaceuticals, Inc.'s common stock?
The par value of Citius Pharmaceuticals, Inc.'s common stock is $0.001, as specified in the filing under 'Title of each class'.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on January 2, 2024, which is also the date of the report, as indicated by 'Date of Report (Date of earliest event reported) January 2, 2024'.
What is the business address and phone number of Citius Pharmaceuticals, Inc.?
Citius Pharmaceuticals, Inc.'s business address is 11 Commerce Drive, 1st Floor, Cranford, NJ 07016, and its telephone number is (908) 967-6677, according to the 'BUSINESS ADDRESS' and 'Registrant’s telephone number' sections of the filing.
Filing Stats: 559 words · 2 min read · ~2 pages · Grade level 10.6 · Accepted 2024-01-02 16:04:14
Key Financial Figures
- $0.001 — nge on which registered Common stock, $0.001 par value CTXR The Nasdaq Capital M
Filing Documents
- ea190916-8k_citius.htm (8-K) — 28KB
- ea190916ex99-1_citius.htm (EX-99.1) — 81KB
- ea190916ex99-2_citius.htm (EX-99.2) — 14KB
- ex99-1_001.jpg (GRAPHIC) — 4KB
- ex99-2_001.jpg (GRAPHIC) — 4KB
- 0001213900-24-000247.txt ( ) — 323KB
- ctxr-20240102.xsd (EX-101.SCH) — 3KB
- ctxr-20240102_lab.xml (EX-101.LAB) — 33KB
- ctxr-20240102_pre.xml (EX-101.PRE) — 22KB
- ea190916-8k_citius_htm.xml (XML) — 3KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On January 2, 2024, we issued a press release announcing our results of operations for the full year of fiscal 2023. A copy of the press release is furnished as Exhibit 99.1 to this report and is incorporated herein by reference. The information in this Item 2.02 (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.
01 Other Events
Item 8.01 Other Events. On January 2, 2024, we issued a press release to announce that we have completed enrollment in the pivotal Phase 3 Trial of Mino-Lok , an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections. A copy of the press release is attached hereto as Exhibit 99.2 to this report and is incorporated by referenced.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release, dated January 2, 2024. 99.2 Press release, dated January 2, 2024 104 Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL). 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CITIUS PHARMACEUTICALS, INC. Date: January 2, 2024 /s/ Leonard Mazur Leonard Mazur Chairman and Chief Executive Officer 2